Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16424613 | 0.99 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL16489799 | 0.88 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL28572864 | 0.85 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL4916421 | 0.85 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL9488076 | 0.84 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL10832186 | 0.82 | MEN1 (0.61) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL27692260 | 0.80 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL22981228 | 0.79 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP2C19 | |
| SCHEMBL28004659 | 0.78 | KMT2A (0.33) | MEN1KMT2ANPSR1 | |
| SCHEMBL29707055 | 0.78 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2L3MBTL1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238667-B2 | Rhodium catalyst and method for producing amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-9238667-B2 | Rhodium catalyst and method for producing amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150051416-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | SPERA PHARMA, INC. (JP) | 2015-02-19 | — | — | US | disclosed |
| US-20150051416-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | SPERA PHARMA, INC. (JP) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051416-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | PRMT7, PRMT5, HNMT | NPC1 1914/4885RAB9A 212/4885SMN1; SMN2 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.